株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

幹細胞を用いた軟骨再生の世界市場 - 市場規模、シェア、見通し、市場機会の分析 2018年~2026年

Stem Cell Cartilage Regeneration Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

発行 Coherent Market Insights 商品コード 785799
出版日 ページ情報 英文 154 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.74円で換算しております。
Back to Top
幹細胞を用いた軟骨再生の世界市場 - 市場規模、シェア、見通し、市場機会の分析 2018年~2026年 Stem Cell Cartilage Regeneration Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
出版日: 2019年01月24日 ページ情報: 英文 154 Pages
概要

変形性関節症の罹患数の世界的な増加が、幹細胞を用いた軟骨再生市場の主な成長要因となっています。また、政府機関による幹細胞治療の導入を向上させる政策も近い将来、当市場の成長を促すと見込まれています。しかし、幹細胞を用いた軟骨再生治療はコストが高く、市場の成長を抑制する要因となっています。

当レポートでは、世界の幹細胞を用いた軟骨再生市場を調査し、市場の概要、幹細胞タイプ・治療・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の概要

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:幹細胞タイプ別
    • 市場スニペット:治療別
    • 市場スニペット:エンドユーザー別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な開発
  • 規制の状況
  • PEST分析

第4章 幹細胞を用いた軟骨再生市場:幹細胞タイプ別

  • イントロダクション
  • 造血幹細胞(HSC)
  • 多能性幹細胞(iPSC / ESC)
  • 間葉系幹細胞(MSC)

第5章 幹細胞を用いた軟骨再生市場:治療別

  • イントロダクション
  • マイクロフラクチャー
  • 軟骨移植
  • 自家軟骨細胞移植
  • 幹細胞注射

第6章 幹細胞を用いた軟骨再生市場:エンドユーザー別

  • イントロダクション
  • 病院・診療所
  • 外来外科センター

第7章 幹細胞を用いた軟骨再生市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • アフリカ
  • 中東

第8章 競争環境

  • 企業プロファイル
    • Theracell Advanced Biotechnology Ltd.
    • Orthocell Ltd.
    • Xintela AB
    • CellGenix GmbH
    • Merck KGaA
    • Osiris Therapeutics, Inc.
    • BioTissue SA
    • Vericel Corporation

第9章 セクション

  • アナリストの意見
  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

In cartilage regeneration, stem cells have the potential for multiple differentiation and self-replication, making it an ideal choice for use as seed cells. Growing regenerative medicine industry and increasing demand for stem cells in the development of various types of cell therapies are expected to drive growth of the market over the forecast period. Mesenchymal stem cells are the most widely applied stem cells in the field of cartilage regeneration.

Market Dynamics

Growing osteoarthritis incidence among the global population is supporting the adoption of stem cell cartilage regeneration therapy. For instance, according to November 2017, Arthritis Foundation data findings, with the increase in global geriatric population, degenerative disease disorders such as osteoarthritis will impact at least 130 million individuals around the globe by 2050.

Furthermore, various government agencies are focusing on policies to enhance adoption of stem cell therapies, which is expected to drive growth of stem cell cartilage regeneration market in the near future. For instance, in December 2016, the 21st Century Cures Act (Cures Act) was signed into law by the U.S. FDA, thereby allowing legislation for an expedited approval path for cellular medicines designated as regenerative medicine advanced therapies (RMATs) to patients who are in need of it.

However, high cost of treatment is expected to hamper the stem cell cartilage regeneration market during the forecast period. Moreover, extensive time and expertise required to perform stem cell based therapy leads to increase the cost of this procedure. In some cases, the physician must pay licensing fees to access stem cell sourcing, processing, or delivering these technologies.

Key features of the study:

  • This report provides in-depth analysis of the stem cell cartilage regeneration market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2018 - 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global stem cell cartilage regeneration market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global stem cell cartilage regeneration market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for stem cell cartilage regeneration market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Stem Cell Cartilage Regeneration Market, By Stem Cell Type:
    • Hematopoietic Stem Cells (HSCs)
    • Pluripotent Stem Cells (iPSC/ESCs)
    • Mesenchymal Stem Cells (MSCs)
  • Global Stem Cell Cartilage Regeneration Market, By Treatment:
    • Microfracture
    • Osteochondral Transplant
    • Autologous Chondrocyte Implantation
    • Stem Cell Injections
  • Global Stem Cell Cartilage Regeneration Market, By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
  • Global Stem Cell Cartilage Regeneration Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Stem Cell Type:
    • Hematopoietic Stem Cells (HSCs)
    • Pluripotent Stem Cells (iPSC/ESCs)
    • Mesenchymal Stem Cells (MSCs)
      • By Treatment:
    • Microfracture
    • Osteochondral Transplant
    • Autologous Chondrocyte Implantation
    • Stem Cell Injections
      • By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Stem Cell Type:
    • Hematopoietic Stem Cells (HSCs)
    • Pluripotent Stem Cells (iPSC/ESCs)
    • Mesenchymal Stem Cells (MSCs)
      • By Treatment:
    • Microfracture
    • Osteochondral Transplant
    • Autologous Chondrocyte Implantation
    • Stem Cell Injections
      • By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Stem Cell Type:
    • Hematopoietic Stem Cells (HSCs)
    • Pluripotent Stem Cells (iPSC/ESCs)
    • Mesenchymal Stem Cells (MSCs)
      • By Treatment:
    • Microfracture
    • Osteochondral Transplant
    • Autologous Chondrocyte Implantation
    • Stem Cell Injections
      • By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Stem Cell Type:
    • Hematopoietic Stem Cells (HSCs)
    • Pluripotent Stem Cells (iPSC/ESCs)
    • Mesenchymal Stem Cells (MSCs)
      • By Treatment:
    • Microfracture
    • Osteochondral Transplant
    • Autologous Chondrocyte Implantation
    • Stem Cell Injections
      • By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Stem Cell Type:
    • Hematopoietic Stem Cells (HSCs)
    • Pluripotent Stem Cells (iPSC/ESCs)
    • Mesenchymal Stem Cells (MSCs)
      • By Treatment:
    • Microfracture
    • Osteochondral Transplant
    • Autologous Chondrocyte Implantation
    • Stem Cell Injections
      • By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Stem Cell Type:
    • Hematopoietic Stem Cells (HSCs)
    • Pluripotent Stem Cells (iPSC/ESCs)
    • Mesenchymal Stem Cells (MSCs)
      • By Treatment:
    • Microfracture
    • Osteochondral Transplant
    • Autologous Chondrocyte Implantation
    • Stem Cell Injections
      • By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
  • Company Profiles
    • Theracell Advanced Biotechnology Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Orthocell Ltd.
    • Xintela AB
    • CellGenix GmbH
    • Merck KGaA
    • Osiris Therapeutics, Inc.
    • BioTissue SA
    • Vericel Corporation

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Stem Cell Type
    • Market Snippet, By Treatment
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Landscape
  • PEST Analysis

4. Global Stem Cell Cartilage Regeneration Market, By Stem Cell Type, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hematopoietic Stem Cells (HSCs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Pluripotent Stem Cells (iPSC/ESCs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Mesenchymal Stem Cells (MSCs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Stem Cell Cartilage Regeneration Market, By Treatment, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Microfracture
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Osteochondral Transplant
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Autologous Chondrocyte Implantation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Stem Cell Injections
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Stem Cell Cartilage Regeneration Market, By End User, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospitals & Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

7. Global Stem Cell Cartilage Regeneration Market, By Region, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Stem Cell Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Treatment, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Stem Cell Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Treatment, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Stem Cell Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Treatment, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Stem Cell Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Treatment, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Stem Cell Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Treatment, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Stem Cell Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Treatment, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Theracell Advanced Biotechnology Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Orthocell Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Xintela AB
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • CellGenix GmbH
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck KGaA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Osiris Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • BioTissue SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Vericel Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Section

  • Analyst Views
  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top